Novo Nordisk successfully completes phase 2 trial with CagriSema in people with type 2 diabetes

Novo Nordisk moment blazoned caption results from a phase 2 clinical trial with CagriSema, a formerly-daily subcutaneous combination of semaglutide and a new amylin analogue, cagrilintide.

The trial delved the efficacity and safety of a fixed cure combination of CagriSema(2.4 mg semaglutide and2.4 mg cagrilintide) compared to the individual factors semaglutide2.4 mg and cagrilintide2.4 mg, all administered formerly weekly, in 92 people with type 2 diabetes and fat. People were inversely randomised among the three treatment arms. In the trial, the mean birth HbA1c was8.4 and the mean birth body weight was 106 kg.
After 32 weeks of treatment, people treated with CagriSema achieved a numerically advanced HbA1c reduction of2.18- points compared to a reduction of1.79- points for people treated with semaglutide and0.93- points with cagrilintide alone. People treated with CagriSema achieved a numerically advanced body weight reduction of15.6 compared to a reduction of5.1 for people treated with semaglutide and8.1 with cagrilintide alone1. In the trial, CagriSema appeared to have a safe and well- permitted profile.

“ We’re encouraged by the emotional phase 2 results for CagriSema in people with type 2 diabetes, ” said Martin Holst Lange, administrative vice chairman for Development at Novo Nordisk. “ The results indicate that CagriSema reduces blood sugar further than semaglutide alone and the weight loss seen in the trial confirms the substantial weight lowering eventuality of CagriSema ”.
Grounded on the results, Novo Nordisk is now planning to initiate a phase 3 development programme for CagriSema in people with type 2 diabetes in 2023. The CagriSema(2.4 mg semaglutide and2.4 mg cagrilintide) phase 3 programme in people with fat and rotundity, review, is anticipated to begin in the fourth quarter of 2022.

About Novo Nordisk
Novo Nordisk is a leading global healthcare company, innovated in 1923 and headquartered in Denmark. Our purpose is to drive change to master diabetes and other serious habitual conditions similar as rotundity and rare blood and endocrine diseases. We do so by introducing scientific improvements, expanding access to our drugs and working to help and eventually cure complaint. Novo Nordisk employs about 50, 8 00 people in 80 countries and requests its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen( Novo- B). Its ADRs are listed on the New York Stock Exchange( NVO).

Source link:https://www.novonordisk.com/